Dr. Daniel Blessing

Inspired by and dedicated to the premise of programable regulatory genome targeted therapeutics and genetic medicines broadly, Dr. Daniel Blessing is Co-Founder and CTO of HAYA Therapeutics. His role at HAYA is focused on leading R&D to devise and execute strategies to bring assets and drug candiadidates from early discovery to the translational IND-Enabling stage.  He was together wis his co-founder Dr. Samir Ounzain (CEO) recognized with the Andreas & Thomas Struengmann Award 2024 for their pioneering entrepreneurial vision. Dr. Blessing's scientific background includes post-doctoral research at the UNiversity Hospital Lausanne (CHUV) in genetic medicines and RNA-targeting therapeutics for the modulation of regulatory genome derive non-coding RNAs and a PhD research at the University of Lausanne/EPFL focused on therapeutic gene delivery and gene therapy approaches using differnt modalities.